Tempus AI: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 2, 2026, Tempus AI (NASDAQ:TEM) reported total revenue of $411.5 million, up 23% year over year. The diagnostic and data platform generated $25.6 million in adjusted EBITDA, or earnings before interest, taxes, depreciation, and amortization. Rising test prices and multiyear biopharma licensing agreements provide predictable funding for future software development. Three things management said on the call stand out. Data and applications revenue rose 33% year over year to $108 million, driven by long-term licensing of real-world patient records to biopharma partners, such as Pathos AI. Multiyear collaborations with major pharmaceutical companies secure predictable cash flows as clients train artificial intelligence models inside the company's platform. Continue reading